Pacific Biosciences of California, Inc. is a premium stock of StocksGuide. Please log in to activate an alert for Pacific Biosciences of California, Inc..
Register for Free
Please register for free to add Pacific Biosciences of California, Inc. to your portfolio.
Pacific Biosciences of California, Inc. Stock News
Enhanced PureTarget portfolio replaces the need for multiple tests with single scalable solution for inherited disease screening Enhanced PureTarget portfolio replaces the need for multiple tests with single scalable solution for inherited disease screening
Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 12:20 PM EDT Company Participants Christian Henry - President, CEO & Director Conference Call Participants Yuko Oku - Morgan Stanley, Research Division Presentation Yuko Oku Equity Analyst Hi. My name is Yuko Oku, and I'm on the life science tools and diagnostics tea...
New addition to PacBio Compatible program enables scientists to connect genetic variation with gene regulation in a single assay, advancing research in rare disease and cancer New addition to PacBio Compatible program enables scientists to connect genetic variation with gene regulation in a single assay, advancing research in rare disease and cancer
Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Christian O. Henry - President, CEO & Director James R.
MENLO PARK, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences:
The most comprehensive, family-based variant dataset ever published will improve variant classification using AI-based tools The most comprehensive, family-based variant dataset ever published will improve variant classification using AI-based tools
New test utilizes technology based on PacBio's PureTarget sequencing method to uncover genetic causes of disease BOSTON , July 29, 2025 /PRNewswire/ -- Athena Diagnostics, the specialty neurology business of Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced a new laboratory test service intended to provide insights into genetic causes of ataxi...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.